Health Canada’s Dealer’s Licence & Section 56 Explained with Benjamin Lightburn
Benjamin Lightburn of Filament Health discusses the ins and outs of being a licensed dealer of naturally derived psilocybin in Canada and internationally.
filament health
Vancouver Company Creates World’s First Ever Ayahuasca Pill
Ayahuasca pills provide users with an easily accessible, safe and convenient way to explore spiritual realms like never before.
Project Solace: The World’s Largest Medical Psilocybin Access and Data Project
Project Solace uses real-world data to inform development of regulated psilocybin therapy, led by Canadian non-profit TheraPsil
3 Microdosing Clinical Trials to Keep an Eye On
Does microdosing psychedelics work, or is it the placebo effect? Here are 3 microdosing clinical trials looking for answers
Psychedelic Business Spotlight – June 17
This week in psychedelic business news: ARK Invest advances deep dive into psychedelic stocks; Cybin moves closer to clinical trials, and more!
Psychedelic Business Spotlight – March 25
This week in psychedelic business news: Filament Health scores 2nd psilocybin patent; a new psychedelics company emerges as one crumbles.
Psychedelic Business Spotlight: November 5
This week in psychedelic business news: DEA grants Cybin a Schedule I manufacturing license; PharmaTher partners with Revive Therapeutics on microneedle patch technology; Mydecine patents nanotechnology.
FDA Approves First Clinical Trial Using Naturally Sourced Psychedelics
This trial, using Filament Health’s botanical drug candidates, is the first to assess the direct administration of psilocin.
Psychedelic Business Spotlight: September 10, 2021
This week in psychedelic business news: major DMT development for stroke treatment; a propriety psilocybin formulation has potential to treat obesity; two more companies join the OTC Pink Market.
Psychedelic Business Spotlight: September 3, 2021
“Magic Truffle” producer and distributor Red Light Holland has had a very busy week, and Filament Health files a “milestone” patent.
End of content
End of content